Metastatic Castration-Resistant Prostate Cancer Patients
Oncology·MeSH: Neoplasms
Prevalence
256.0 / 100K
Incidence
111.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
Frequently asked questions
How many drugs are in development for Metastatic Castration-Resistant Prostate Cancer Patients?
BioSniper tracks 1 drug in development for Metastatic Castration-Resistant Prostate Cancer Patients across 1 company.
How many clinical trials target Metastatic Castration-Resistant Prostate Cancer Patients?
There are 1 clinical trial targeting Metastatic Castration-Resistant Prostate Cancer Patients tracked by BioSniper.
What is the prevalence of Metastatic Castration-Resistant Prostate Cancer Patients?
The estimated prevalence of Metastatic Castration-Resistant Prostate Cancer Patients is approximately 256.0 per 100,000 population.
Deep-dive into Metastatic Castration-Resistant Prostate Cancer Patients
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis